These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17308913)

  • 1. [Drug trials in humans. Risks in the light of the London catastrophe].
    Otte A
    Internist (Berl); 2007 Jun; 48(6):636-41. PubMed ID: 17308913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [After the TGN1412 incident. Principles for assessment of first-in-man trials with monoclonal antibodies by the Paul Ehrlich Institute].
    Schneider CK; Kalinke U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Oct; 50(10):1213-20. PubMed ID: 17924065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on TGN1412.
    Bhogal N; Combes R
    Altern Lab Anim; 2006 Jun; 34(3):351-6. PubMed ID: 16831066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
    Tranter E; Peters G; Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Aug; 76(2):164-72. PubMed ID: 23438102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.
    Hünig T
    FEBS J; 2016 Sep; 283(18):3325-34. PubMed ID: 27191544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.
    Liedert B; Bassus S; Schneider CK; Kalinke U; Löwer J
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):1-9. PubMed ID: 17256444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primate testing of TGN1412: right target, wrong cell.
    Pallardy M; Hünig T
    Br J Pharmacol; 2010 Oct; 161(3):509-11. PubMed ID: 20880391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The calm after the cytokine storm: lessons from the TGN1412 trial.
    St Clair EW
    J Clin Invest; 2008 Apr; 118(4):1344-7. PubMed ID: 18357347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and side effects of monoclonal antibodies.
    Hansel TT; Kropshofer H; Singer T; Mitchell JA; George AJ
    Nat Rev Drug Discov; 2010 Apr; 9(4):325-38. PubMed ID: 20305665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.
    Mehrishi JN; Szabó M; Bakács T
    Vaccine; 2007 May; 25(18):3517-23. PubMed ID: 17397974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
    Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
    J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. London's disastrous drug trial has serious side effects for research.
    Wadman M
    Nature; 2006 Mar; 440(7083):388-9. PubMed ID: 16554763
    [No Abstract]   [Full Text] [Related]  

  • 15. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.
    Dayan CM; Wraith DC
    Clin Exp Immunol; 2008 Feb; 151(2):231-4. PubMed ID: 18190459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing risk of human experimentation with drugs: lessons from TGN1412.
    Kenter MJ; Cohen AF
    Lancet; 2006 Oct; 368(9544):1387-91. PubMed ID: 17046471
    [No Abstract]   [Full Text] [Related]  

  • 17. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
    Hünig T
    Nat Rev Immunol; 2012 Apr; 12(5):317-8. PubMed ID: 22487653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD28 superagonists: what makes the difference in humans?
    Schraven B; Kalinke U
    Immunity; 2008 May; 28(5):591-5. PubMed ID: 18482560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Northwick Park tragedy--protecting healthy volunteers in future first-in-man trials.
    Dowsing T; Kendall MJ
    J Clin Pharm Ther; 2007 Jun; 32(3):203-7. PubMed ID: 17489872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.